参考文献/References:
[1]Iacobellis G. Epicardial adipose tissue in contemporary cardiology[J]. Nat Rev Cardiol,2022,19(9):593-606.
[2]Myasoedova VA,Parisi V,Moschetta D,et al. Efficacy of cardiometabolic drugs in reduction of epicardial adipose tissue:a systematic review and meta-analysis[J]. Cardiovasc Diabetol,2023,22(1):23.
[3]Iacobellis G ,Corradi D,Sharma AM. Epicardial adipose tissue:anatomic,biomolecular and clinical relationships with the heart[J]. Nat Clin Pract Cardiovasc Med,2005,2(10):536-543.
[4]Guglielmo M,Lin A,Dey D,et al. Epicardial fat and coronary artery disease:role of cardiac imaging[J]. Atherosclerosis,2021,321:30-38.
[5]Gaborit B,Abdesselam I,Dutour A. Epicardial fat:more than just an “epi” phenomenon?[J]. Horm Metab Res ,2013,45(13):991-1001.
[6]Tarsitano MG,Pandozzi C,Muscogiuri G,et al. Epicardial adipose tissue:a novel potential imaging marker of comorbidities caused by chronic inflammation[J]. Nutrients,2022,14(14):2926.
[7]Iacobellis G,Assael F,Ribaudo MC,et al. Epicardial fat from echocardiography:a new method for visceral adipose tissue prediction[J]. Obes Res,2003,11(2):304-310.
[8]Hendricks S,Dykun I,Balcer B,et al. Epicardial adipose tissue is a robust measure of increased risk of myocardial infarction—A meta-analysis on over 6600 patients and rationale for the EPIC-ACS study[J]. Medicine(Baltimore),2021,100(52):e28060.
[9]Leo LA,Paiocchi VL,Schlossbauer SA,et al. The intrusive nature of epicardial adipose tissue as revealed by cardiac magnetic resonance[J]. J Cardiovasc Echogr,2019,29(2):45-51.
[10]Zhang L,Sun J,Jiang B,et al. Development of artificial intelligence in epicardial and pericoronary adipose tissue imaging:a systematic review[J]. Eur J Hybrid Imaging,2021,5(1):14.
[11]Chou R,Cantor A,Dana T,et al. Statin use for the primary prevention of cardiovascular disease in adults:updated evidence report and systematic review for the US Preventive Services Task Force[J]. JAMA,2022,328(8):754-771.
[12]Parisi V,Petraglia L,D’Esposito V,et al. Statin therapy modulates thickness and inflammatory profile of human epicardial adipose tissue[J]. Int J Cardiol,2019,274:326-330.
[13]Murphy RA,Register TC,Shively CA,et al. Adipose tissue density,a novel biomarker predicting mortality risk in older adults[J]. J Gerontol A Biol Sci Med Sci,2014,69(1):109-117.
[14]Marwan M,Hell M,Schuhb?ck A,et al. CT attenuation of pericoronary adipose tissue in normal versus atherosclerotic coronary segments as defined by intravascular ultrasound[J]. J Comput Assist Tomogr,2017,41(5):762-767.
[15]Raggi P,Gadiyaram V,Zhang C,et al. Statins reduce epicardial adipose tissue attenuation independent of lipid lowering:a potential pleiotropic effect[J]. J Am Heart Assoc,2019,8(12):e13104.
[16]Cheng K,Hii R,Lim E,et al. Effect of statin therapy on coronary inflammation assessed by pericoronary adipose tissue computed tomography attenuation[J]. Eur Heart J Cardiovasc Imaging,2025,26(5):784-793.[17]Glerup S,Schulz R,Laufs U,et al. Physiological and therapeutic regulation of PCSK9 activity in cardiovascular disease[J]. Basic Res Cardiol,2017,112(3):32.[18]Dozio E,Ruscica M,Vianello E,et al. PCSK9 expression in epicardial adipose tissue:molecular association with local tissue inflammation[J]. Mediators Inflamm,2020,2020:1348913.[19]Rivas Galvez RE,Morales Portano JD,Trujillo Cortes R,et al. Reduction of epicardial adipose tissue thickness with PCSK9 inhibitors[J]. Eur Heart J,2020,41(supplement_2):ehaa946.3008.[20]Cowie MR,Fisher M. SGLT2 inhibitors:mechanisms of cardiovascular benefit beyond glycaemic control[J]. Nat Rev Cardiol,2020,17(12):761-772.
[21]Iacobellis G,Leonetti F. Epicardial adipose tissue and insulin resistance in obese subjects[J]. J Clin Endocrinol Metab,2005,90(11):6300-6302.[22]Díaz-Rodríguez E,Agra RM,Fernández ?L,et al. Effects of dapagliflozin on human epicardial adipose tissue:modulation of insulin resistance,inflammatory chemokine production,and differentiation ability[J]. Cardiovasc Res,2018,114(2):336-346.[23]Braha A,Timar B,Diaconu L,et al. Dynamics of epicardiac fat and heart function in type 2 diabetic patients initiated with SGLT-2 inhibitors[J]. Diabetes Metab Syndr Obes,2019,12:2559-2566.[24]Song XT,Wei YL,Rui YF,et al. Echocardiographic evaluation of the effect of dapagliflozin on epicardial adipose tissue and left ventricular systolic function in type 2 diabetes mellitus[J]. J Diabetes Complications,2023,37(7):108509.[25]Takano M,Kondo H,Harada T,et al. Empagliflozin suppresses the differentiation/maturation of human epicardial preadipocytes and improves paracrine secretome profile[J]. JACC Basic Transl Sci,2023,8(9):1081-1097.[26]Cinti F,Leccisotti L,Sorice GP,et al. Dapagliflozin treatment is associated with a reduction of epicardial adipose tissue thickness and epicardial glucose uptake in human type 2 diabetes[J]. Cardiovasc Diabetol,2023,22(1):349.[27]Szekeres Z,Nagy A,Jahner K,et al. Impact of selected glucagon-like peptide-1 receptor agonists on serum lipids,adipose tissue,and muscle metabolism—A narrative review[J]. Int J Mol Sci,2024,25(15):8214.[28]Marsico F,Paolillo S,Gargiulo P,et al. Effects of glucagon-like peptide-1 receptor agonists on major cardiovascular events in patients with type 2 diabetes mellitus with or without established cardiovascular disease:a meta-analysis of randomized controlled trials[J]. Eur Heart J,2020,41(35):3346-3358.[29]Iacobellis G,Camarena V,Sant DW,et al. Human epicardial fat expresses glucagon-like peptide 1 and 2 receptors genes[J]. Horm Metab Res,2017,49(8):625-630.[30]Iacobellis G,Villasante Fricke AC. Effects of semaglutide versus dulaglutide on epicardial fat thickness in subjects with type 2 diabetes and obesity[J]. J Endocr Soc,2020,4(4):bvz042.[31]Zhao N,Wang X,Wang Y,et al. The effect of liraglutide on epicardial adipose tissue in type 2 diabetes[J]. J Diabetes Res,2021,2021:5578216.[32]Li T,Providencia R,Jiang W,et al. Association of metformin with the mortality and incidence of cardiovascular events in patients with pre-existing cardiovascular diseases[J]. Drugs,2022,82(3):311-322.[33]Ziyrek M,Kahraman S,Ozdemir E,et al. Metformin monotherapy significantly decreases epicardial adipose tissue thickness in newly diagnosed type 2 diabetes patients[J]. Rev Port Cardiol (Engl Ed),2019,38(6):419-423.[34]Lima-Martínez MM,Paoli M,Rodney M,et al. Effect of sitagliptin on epicardial fat thickness in subjects with type 2 diabetes and obesity:a pilot study[J]. Endocrine,2016,51(3):448-455.[35]Moody AJ,Molina-Wilkins M,Clarke GD,et al. Pioglitazone reduces epicardial fat and improves diastolic function in patients with type 2 diabetes[J]. Diabetes Obes Metab,2023,25(2):426-434.
相似文献/References:
[1]白春兰,张军.正五聚蛋白-3:新型心血管病炎性标志物[J].心血管病学进展,2016,(1):87.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.023]
BAI Chunlan,ZHANG Jun.Pentraxin-3: A Novel Inflammation Biomarker for Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2016,(10):87.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.023]
[2]郑涛,综述,凌智瑜,等.心外膜脂肪组织与心房颤动[J].心血管病学进展,2016,(4):372.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.012]
ZHENG Tao,LING Zhiyu.Epicardial Adipose Tissue and Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(10):372.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.012]
[3]任茂佳,贺文帅,张琪,等.围绝经期对心血管疾病相关危险因素的影响[J].心血管病学进展,2019,(6):911.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.018]
REN Maojia,HE Wenshuai,ZHANG Qi,et al.Effects of Perimenopause on Cardiovascular Risk Factors[J].Advances in Cardiovascular Diseases,2019,(10):911.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.018]
[4]尹琳 黄从新.JP2蛋白和心血管疾病的研究进展[J].心血管病学进展,2019,(7):1004.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.010]
YIN Lin HUANG Congxin.Research Progress of JP2 Protein and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(10):1004.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.010]
[5]朱峰 汪汉 蔡琳.抗体与心血管疾病[J].心血管病学进展,2019,(7):1007.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.011]
ZHU FengWANG HanCAI Lin.Antibodies and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(10):1007.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.011]
[6]邱明仙 王正龙 许官学.心肌肌球蛋白结合蛋白-C磷酸化与心血管疾病关系的研究进展[J].心血管病学进展,2019,(7):1015.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.013]
QIU MingxianWANG ZhenglongXU Guanxue.Research Progress of the Relationship Between Cardiac Myosin Binding Protein-C and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(10):1015.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.013]
[7]姬楠楠 杨晓静 谢勇.单核细胞/高密度脂蛋白比值与心血管疾病的研究进展[J].心血管病学进展,2019,(7):1019.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.014]
JI Nannan YANG Xiaojing XIE Yong.Monocyte/High-density Lipoprotein Ratio and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(10):1019.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.014]
[8]渠海贤 李涛 程流泉.人工智能在心脏磁共振成像中的应用进展[J].心血管病学进展,2019,(5):659.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.001]
[9]侯冬华 郝丽荣.长正五聚蛋白3在动脉粥样硬化和心血管疾病中作用研究的新进展[J].心血管病学进展,2019,(5):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
HOU Donghua H AO Lirong.The Study of Atherosclerosis and Cardiovascular Diseases with Pentapycin 3[J].Advances in Cardiovascular Diseases,2019,(10):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
[10]张维 张恒 康品方.外泌体在心血管疾病中的研究进展[J].心血管病学进展,2019,(5):818.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.038]
Zhang WeiKang Pinfang.Exosome in Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(10):818.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.038]
[11]张瑶 王鑫 王鹏 李瑾.心外膜脂肪组织在心力衰竭中的研究进展[J].心血管病学进展,2023,(11):1010.[doi:10.16806/j.cnki.issn.1004-3934.2023.11.012]
ZHANG YaoWANG XinWANG PengLI Jin.Epicardial Adipose Tissue in Heart Failure[J].Advances in Cardiovascular Diseases,2023,(10):1010.[doi:10.16806/j.cnki.issn.1004-3934.2023.11.012]